Invention Grant
- Patent Title: Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
-
Application No.: US15182775Application Date: 2016-06-15
-
Publication No.: US10308717B2Publication Date: 2019-06-04
- Inventor: Jennifer Brogdon , Laura Alexandra Johnson , Carl H. June , Andreas Loew , Marcela Maus , John Scholler , Hideho Okada
- Applicant: Novartis AG , The Trustees of the University of Pennsylvania , University of Pittsburgh—of the Commonwealth System of Higher Education
- Applicant Address: CH Basel US PA Philadelphia US PA Pittsburgh
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania,University of Pittsburgh—of The Commonwealth System of Higher Education
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania,University of Pittsburgh—of The Commonwealth System of Higher Education
- Current Assignee Address: CH Basel US PA Philadelphia US PA Pittsburgh
- Agency: Lando & Anastasi, LLP
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K38/00 ; C07K16/30 ; A61K35/17 ; A61K39/00
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
Public/Granted literature
- US20170008963A1 TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR Public/Granted day:2017-01-12
Information query
